DB Asset Management Launches Fund Investing Simultaneously in Korean and Chinese Bio-Healthcare Sectors

On November 3, DB Asset Management announced the launch of the "DB Tiger Dragon Bio Healthcare Target Conversion Type Securities Investment Trust [Mixed Equity]," a fund focusing on the bio-healthcare sectors in Korea and China, both of which have significant growth potential.

DB Asset Management, which established Korea's first domestic bio-healthcare fund in 2009, has been managing a China bio-healthcare fund since 2019. The company has accumulated deep understanding and expertise in the healthcare industry.

The bio-healthcare industry is creating new markets, driven by structural growth factors such as population aging and the rise of chronic diseases, as well as advancements in innovative technologies like AI drug development, gene editing, and cell therapies. Since the COVID-19 pandemic, governments around the world have recognized biotechnology as an economic security asset and have implemented strong industrial support policies, including regulatory easing and increased R&D investment.

The "DB Tiger Dragon Bio Healthcare Target Conversion Type Securities Investment Trust [Mixed Equity]" combines Korea's innovative technologies with China's vast market potential. It is expected to be an attractive option for investors seeking both returns and stable management after achieving their investment goals in the highly volatile bio market.

A representative from DB Asset Management stated, "The DB Tiger Dragon Bio Healthcare Target Conversion Type Fund pursues returns by diversifying investments in the structurally growing bio-healthcare sectors of Korea and China," adding, "When the target return rate of 10% is achieved, the fund will automatically convert to a bond-type investment, offering an opportunity to secure stability."

This content was produced with the assistance of AI translation services.